acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.
NEC Corporation: Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of.
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation activity to.
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.